Resultados de Búsqueda por Autor

artículo

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

Publicado por
Albain, KS, Gray, RJ, Makower, DF, Faghih, A, Hayes, DF, Geyer, CE, Dees, EC, Goetz, MP, Olson, JA, Lively, T, Badve, SS, Saphner, TJ, Wagner, LI, Whelan, TJ, Ellis, MJ, Wood, WC, Keane, MM, Gomez, HL, Reddy, PS, Goggins, TF, Mayer, IA, Brufsky, AM, Toppmeyer,DL, Kaklamani, VG, Berenberg, JL, Abrams, J, Sledge, GW, Sparano, JA

Publicado 2021

Enlace

Background: Black race is associated with worse outcomes in early breast cancer. We evaluated clinicopathologic characteristics, the 21-gene recurrence score (RS), treatment delivered, and clinical outcomes by race and ethnicity among women who participated in the Trial Assigning Individualized Options for Treatment. Methods: The association between clinical outcomes and race (White, Black, Asian, other or unknown) and ethnicity (Hispanic vs non-Hispanic) was examined using proportional hazards models. All P values are 2-sided. Results: Of 9719 eligible women with hormone receptor-positive, HER2-negative, node-negative breast cancer, there were 8189 (84.3%) Whites, 693 (7.1%) Blacks, 405 (4.2%) Asians, and 432 (4.4%) with other or unknown race. Regarding ethnicity, 889 (9.1%) were Hispanic. There were no substantial differences in RS or ESR1, PGR, or HER2 RNA expression by race or ethnic...